|%/lẽtered-close inhalers are a convenient means of administering bronchodilator aerosol to asth matic subjects. A recent study1 has emphasized that the correct use of these inhalers is important to achieve the best improvement in ventilatory func tion with the bronchodilator drug; however, another uncontrolled study in children has suggested that buccal administration of the aerosol results in sig nificant bronchodilatation.2 If this latter suggestion is true, then theories regarding the local effect of adrcncrgic bronchodilator drugs on /2-adrenergic re ceptors in the airways3 must be reconsidered. In addition, it would mean that an enormous amount of time is being wasted by physicians and nursing per sonnel instructing patients in the use of the metereddose inhaler.
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We have examined the effects of administration of a placebo, of buccal administration of a solution containing 500/xg of fenoterol, and of inhalation of 20(Vg and 4()0yugof fenoterol on ventilatory function in a group of asthmatic subjects in a double-blind randomized study, in order to determine whether the administration of a /Â£>-adrenergicagonist to the buccal mucosa has any significant bronchodilator effect. Fenoterol is chemically derived from metaproterenol by the substitution of a p-hydroxyphenyl group for a hydrogen atom on the N-isopropyl group of metaproterenol. In vitro studies* have shown that this increased bulkiness of the N substituent in feno terol results in an increased selectivity for /^2-adrenergic receptors by this adrenergic agonist, as com pared to metaproterenol.
MATERIALS ANDMETHODS
Ten asthmatic subjects who had previously shown an improvement of 20 percent or more in the forced expiratory volume in one second (FEV,) within 15 minutes after inhalation of albuterol (salbutamol; 200,ug) were selected from the Chest and Allergy Clinic at St. Joseph's Hospital, Hamilton, Ontario. The characteristics of the subjects are shown in Table 1 . Subjects with significant cardiac, renal, hepatic, or metabolic disease were excluded from the study, as were subjects with an FEV, of less than 1 L. All days of study commenced after a 15-minute resting period, at the same time of day for each subject. Where possible, studies were conducted on consecutive days, providing the baseline FEVj was within Â±15 percent of the first day's value. No subject inhaled any bronchodilator drug for eight hours before each day of study. One subject who had been receiv ing oral therapy with theophylline omitted this therapy for 24 hours before each day; seven subjects who had been receiv ing aerosol therapy with beclomethasone dipropionate and one subject who was receiving oral therapy with prednisone T, oral therapy with thcopliylline; and P, oral therapy with prednisone.
continued these medications in their usual dosage.
Ventilatory function was determined by measuring the FEV,, the mean forced expiratory flow over the middle half of the forced vital capacity (FEF25-75!?), and the forced vital capacity (FVC) from the best of three spirograms recorded on a single-breath bellows spirometer (Vitalograph). All volumes were measured at body temperature and pressure, saturated with water vapor. Measurements of ventilatory function were made just before administration of the drug or placebo and at 30-minute intervals for the four hours after administration. Measurements of blood pressure and pulse rate were made just before administration of the drug or placebo and at 60-minute intervals for the four hours after administration.
On each of the four days of study, each subject received one of the treatments after baseline measurements. Each day of study employed two aerosol inhalations and a buccal administration of the appropriate combination of active drug and placebo, so that the effective treatments were as follows: (1) The design of the study was for crossover treatment in a randomized double-blind fashion. At the completion of each four-hour period of study, 200/tg of albuterol was adminis tered to each subject so that reversibility of obstruction of the airways was documented.
Before commencing the study, each subject was trained to use the metered-dose inhaler in the following manner: hold the canister 3 cm away from the wide open mouth, and actuate the canister just after the start of a slow inspiration from functional residual capacity to total lung capacity (TLC), and then hold breath at TLC for ten seconds. \Vritten informed consent was obtained from each subject, and the project was approved by the Ethical Review Com mittee of St. Joseph's Hospital.
The changes in ventilatory function, blood pressure, and pulse rate from the baseline value of that day were calcu lated for each subject on each day of study. In addition, the area under the curve of FEV,, which estimates the degree and duration of bronchodilator effect, was calculated for each subject on each day of study. Statistical analysis was per formed by a two-way analysis of variance and multiple comparison test.0
RESULTS
The mean baseline values of ventilatory function, blood pressure, and pulse rate on the three days of administration of fenoterol were not significantly different from those on the day when placebo was given (P > 0.05) ( Table 2 ). The increases in FEVi achieved after inhalation of the 200/ig and the 400^g doses of fenoterol were not significantly different for the entire four hours after administration (P > 0.05) but were significantly greater (P < 0.01) than the increases achieved after buccal administration of 500/jg of fenoterol and after administration of placebo for the entire four-hour period (Fig 1) . The increases in FEVi achieved after administration of placebo and buccal administration of 500/xg of feno terol were not significantly different during the study (P>0.05).
Similar trends were seen with the increases in FEF25-75? above baseline (Fig 2) and the in creases in FVC above baseline (Fig 3) . The level of significance for the differences in the effects of in halation of 200jug and 400^g of fenoterol from the effects of buccal administration of 500/*gof fenoterol and administration of placebo was P < 0.05 for FEF25-75? and FVC. These significant differences were present throughout the four-hour period of study for FVC (Fig 3) but were not present at 180 to 240 minutes for FEF25-75? in the comparison of There was no significant differ ence between the effects of inhalation of 200ytigand 400yug of fenoterol (P > 0.05), but both inhaled doses produced a greater area under the curve of FEVi than buccal administration of 500/^g of feno terol (P < 0.01). The inhalation of 200,ug of albuterol at the com pletion of each day of study did not result in a higher mean value for FEVi or FVC than that achieved after inhalation of 400/ug of fenoterol but did cause a higher mean value of FEF25-75%. The differences between these effects were not signifi cant (P > 0.05). Each subject showed an increase in FEVi of greater than 20 percent after the inhala tion of albuterol on the days of administration of placebo or of buccal administration of 500/xg of fenoterol.
None of the pharmacologic treatments had a sig nificant effect on blood pressure or pulse rate (P > 0.05), compared to the placebo (Table 3) . Three subjects developed tremor after inhalation of 400/xg of fenoterol. No subject developed tremor after ad ministration of the other dosages of fenoterol or after albuterol.
DISCUSSION
This study has shown that 500/xg of fenoterol administered to the buccal mucosa has no significant bronchodilator effect compared to smaller inhaled doses of fenoterol. In our method, a solution of 500/ig of fenoterol was placed in the oral cavity to avoid any chance that some of this drug might be inhaled as an aerosol. Although it is known that more than 90 percent of the dose from a metereddose inhaler is deposited in the mouth6 and that some of this is swallowed, the amount of absorption through the buccal mucosa is unknown. In fact, some investigators have assumed that all of the drug deposited in the mouth is swallowed and absorbed by the intestinal tract,6 and this assumption is sup ported by recent pharmacokinetic data7 showing that the course over time of plasma levels of radioac tive tritium-labelled fenoterol was similar for both aerosol and oral administration. By having each subject swirl the solution of fenoterol around the mouth and then gargle the solution before swallowing, we have obtained diffuse expo sure of the oral cavity to the drug, which is similar to (but not necessarily identical to) that obtained after use of a metered-dose inhaler. A larger dose of fenoterol was given to the buccal mucosa than either inhaled dose in order to overcome possible differ ences in the buccal absorption of aerosols and solu tions. The intestinal absorption of the swallowed fenoterol did not cause a bronchodilator response. This is to be expected, since even if all of the bucally administered fenoterol was absorbed in the intes tinal tract, the dose is only 20 percent of the dose recommended for oral therapy.
There are no published data comparing the effects of inhalation of 200/ig and 400/ng of fenoterol, but Minette8 has shown that inhalation of 400/xg of fenoterol causes slightly greater bronchodilatation than inhalation of 200/tg of albuterol. Our results suggest that inhalation of 200/xg of fenoterol from a metered-dose inhaler is as effective as 400/xg in pro ducing bronchodilation measured by improvement in FEVi and FEF25-75$; however, the 40<Vg dose of fenoterol did produce a significantly greater in crease in FVC than the 200^g dose.
It is likely that the result reported by Shore et al2
of the effectiveness of a metered dose sprayed into the mouth was due to the small amount of aerosol inhaled, rather than to any effect on postulated /?2-adrenergic receptors in the mouth or an effect of the absorbed /Ss-adrenergic agonist. It is relevant to note that Shore et al2 studied children in an uncontrolled fashion, whereas the present study was controlled and was performed in adults. The results of this study dispel any doubts about the site of action of /?2-adrenergic bronchodilator drugs. The drug must be inhaled into the airways to produce maximum bron chodilator effect as measured by forced expired vol umes.
